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In the United States, the Advisory Committee on Immunization Practices (ACIP) makes 
recommendations as to which cohorts (identified groups of individuals) ought to have higher priority 
access to vaccines when their supply is insufficient to immunize all susceptible individuals in the country. 
Typically, cohorts are determined based on susceptibility to contracting seasonal influenza and on the 
resulting consequences of infection for different age groups. For seasonal influenza, high-risk cohorts 
commonly include children, teenagers, pregnant women and people with different chronic diseases. This 
study proposes the application of revenue management theory to better allocate seasonal influenza 
vaccines among different risk-based population cohorts. Our model maximizes the number of immunized 
individuals by dynamically adjusting the price per dose in each cohort as to discourage vaccination in 
low-risk cohorts and preserve more supply for high-risk cohorts. Experimental results show that up to 
12% of infections and deaths due to seasonal influenza could be avoided by implementing this price 
discrimination policy in hypothetical yet realistic scenarios.  
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In the United States, seasonal influenza claims over 40,000 lives every year [1]. In the case of influenza 
pandemics, the number of cases increases dramatically because the entire population is susceptible to new 
and highly infectious virus strain [2]. For example, the 1918 Spanish Flu pandemic killed 40 million 
people and infected nearly a quarter of the entire global population at the time [3].  
Every year, about 80 million seasonal influenza vaccines are available for distribution to less than 
one-third of the American population [4]. Such a limited supply of seasonal influenza vaccines is due to 
the lack of availability of the eggs that are needed to cultivate the virus used in vaccine manufacturing. 
Therefore, health care authorities must determine how to distribute the limited supply of seasonal 
vaccines to provide the most effective protection across the population. The World Health Organization 
(WHO) [5], among other agencies, refers to ‘herd immunity’ as the minimum proportion of the 
population that needs to be immune to interrupt an infectious disease transmission, which is achieved by 
reducing the probability of infection of those individuals who have yet to develop immunity to the 
disease. Since the basic reproduction number, R0, measures the rate at which the disease spreads, herd 
immunity is achieved when R0 becomes less than one [5].  
Several epidemiological models have been developed to describe the progression and spread of 
infectious diseases (See Hethcote [6] as well as Sattenspiel and Lloyd [7] for further detail.) These models 
are useful to plan and establish effective containment interventions, including vaccination [8, 9], 
behavioral interventions such as school closures [5, 10-12], or their combination [13, 14]. Most 
epidemiological models are compartmentalized systems that describe the disease progression resulting 
from having different compartmental transition rates [15, 16], in which the progression depends on a 
deterministic basic reproduction number (R0), representing the average number of people that are infected 
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by a contagious individual [17]. However, these models have been criticized due to their reliance on R0 
which is assumed to be static. Several alternatives have been suggested; for example, Larson [18] 
proposes an approach that considers that R0 is dynamic and not necessarily homogeneous even for the 
same population and influenza strain. 
In the United States, the ACIP makes recommendations to the population on how to divide people 
into two distinct cohorts based on the vulnerability toward the influenza [19]. ACIP also suggests which 
cohort should have priority access to available vaccination [20]. Based on data from the three past 
influenza pandemics of the twentieth century, Meltzer, Cox and Fukuda [21] claims that an identifiable 
fifteen percent of the population is accountable for causing over four fifths of the infections in each 
pandemic. 
During a pandemic scenario, the US government pays for the cost of vaccines ahead of time, and the 
general population only pays for the price of its delivery, often defrayed through insurance coverage. 
Additionally, the federal and local governments are responsible for determining the most adequate 
distribution of the vaccines to hospitals, clinics and medical centers [22]. During the 2009 influenza 
season, some health care centers denied vaccination to patients that were not in the high-risk cohorts, 
while many other vaccination clinics had concerns about the likelihood that those who were denied 
vaccination be properly vaccinated in the future [23]. 
In 2009, the rapid production of the H1N1 vaccine gave the population the chance to protect 
themselves against a strain of the virus that was unknown until that time. The CDC enforced preferential 
access to vaccines to those considered within the high-risk groups, as recommended by the ACIP [20]. 
The first vaccines delivered were, thus, destined toward vaccination centers that cater to individuals in 
high-risk cohorts, such as “pediatricians, ob/gyns, community health centers and private and public 
hospitals” [22]. However, its limited supply and fear in the population made this vaccine a commodity in 
high demand [24]. 
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Mullen [20] indicates that locations that had been assigned vaccines were asked to “sign an agreement 
to vaccinate only people in the five groups at most risk.” However, this policy was not enforced by the 
authorities, and anyone requesting vaccination was immunized. In this sense, Sadanand [24] notes that 
some corporations received vaccines for their employees prior to hospitals and clinics, resulting in an 
“embarrassing mistake [during the] distribution process.” Nevertheless, McKay [22] concluded that most 
corporations promised to adhere to the CDC’s guidelines, and others willingly turned over their share of 
doses to hospitals that had insufficient vaccine supply. 
At the beginning of the influenza season, the entire population is susceptible to the virus. Vaccination 
is the only method that ensures avoidance of death and infections. However, the limited number of 
vaccines that can be produced with available methods proofs to be practically impossible to vaccinate the 
entire population. Alternatively, selectively vaccinating a fraction of the population to quickly achieve 
herd immunity can minimize the probability of infection. 
This study proposes an alternative methodology to help public-health decision-makers at CDC 
postpone vaccine demand of low-risk individuals so that those in more at-risk cohorts have preferential 
access to vaccines, while trying to minimize the total number of infections and deaths caused during an 
influenza season. Due to the limited supply of seasonal influenza vaccine available to the population, this 
study assumes that health care decision-makers need to persuade cautious individuals from the low-risk 
cohort to opt for vaccination later in the flu season. This study considers that without an intervention from 
authorities, such cautious individuals are likely to use vaccines that could be used early in the season to 
immunize people in high-risk cohorts [25]. 
The proposed methodology delays vaccination of low risk individuals, and prioritizes vaccination of 
high risk cohorts in the early stages of the influenza season. A deterministic disease spread model is 
developed to replicate the effect of the influenza virus on the US population when a vaccine strategy is 
implemented. Specifically, this study aims to answer whether the allocation of vaccines can be more 
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effective if distribution rules based on the cohorts’ risk levels are strictly enforced for the duration of the 
season. 
This study proposes a price discrimination strategy to optimally allocate vaccines among the US 
population.  
The structure of this thesis is as follows. Chapter 1 presents a literature review regarding models for 
analyzing the spread of contagious diseases, Discrete Event-graph simulation, Revenue Management, and 
Price Discrimination, which will be used to in the model formulations of Chapter 2. Two modeling 
approaches are explored: a simulation model and a daily optimization model to minimize the number of 
infections and deaths in the population, focused on enforcing the recommendations by the ACIP. 
Chapter 2 introduces two compartmental stage models of a disease transmission along with its 
corresponding parameters. The vaccination process is presented as a compartmental stage that is 
integrated within the disease spread models. All models’ assumptions and limitations are also discussed. 
Experimental results are presented in Chapter 3. Conclusions and future work are presented in 








This chapter presents background information on theories that will be used throughout this study. The 
first section considers different epidemiological methods that have been widely used to model contagious 
diseases. The second section describes the use of revenue management in industry in order to assess how 
it can be tied to the distribution of vaccines. The final section of the chapter surveys price discrimination 
and discusses two different approaches, price and quantity discrimination, along with an example of the 
application to the influenza case. 
 
1.1 Modeling Contagious Diseases 
 
The ‘SIR’ model is the most commonly used model for explaining the spread of infectious diseases. The 
acronym SIR describes the different health states that an individual undergoes through an infection. Thus, 
in this model, an initially Susceptible (S) individual may become Infectious (I) when he or she contacts an 
already infected individual, and the infected individual becomes Recovered (R) when he or she is not 
infectious anymore [26]. Gani and Leach [27] incorporate two infectious stages, instead of one, as an 
extension of the basic SIR model. The first of such stages corresponds to an asymptomatic but contagious 
state; and the second one corresponds to an infectious and symptomatic stage. The modified SIR has been 
used to analyze the effect of social distancing (voluntary or policy-induced), which reduces the contact 
rate of the individuals that are diagnosed with the particular disease [14, 18, 27, 28]. 
Other extensions to the SIR model include alternatives to the recovery stage, which are typically used 
to consider highly infectious diseases [28, 29]. Modeling vaccine effects to a disease transmission 
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becomes crucial when establishing policies in the case of pandemics.  Along with the recovery state, in 
which patients get healthy and acquire immunity, Cahill et al. [8], for example, adds a stage in which 
patients are vaccinated. He uses a differential equation approach to analyze the effect of vaccines 
introduced to a system, and evaluates their efficacy within it.  
The transmission of an infectious diseases requires that a susceptible individual comes into contact 
with an infected one [30]. Such encounters are usually modeled by estimating the average number of 
contacts that a person may have on a particular day with infectious individuals. This contact rate assumes 
that the entire population is homogenous and everyone in the population has the same probability of being 
infected [8, 31]. While this approach has been validated when modeling the behavior of animals, 
heterogeneous models are preferred for human modeling because they are able to better explain the 
disease transmission among diverse populations and therefore yield more realistic results [32, 33]. 
Hethcote [34] claims that the population cohorts may be determined based on disease-related 
characteristics or on population-specific factors; i.e., heterogeneous groupings. Wallinga, Teunis and 
Kretzchmar [33] have shown through a survey study that individuals’ behavior change based on their age 
groups and, therefore, their contact rate will be altered accordingly, and that the highest contact rate from 
any cohort occurs among individuals in the same age group [35]. More specifically, Stroud et al. [29] 
consider the differences among different groups of people  –preschool, youth, adult and senior– when 
modeling pandemic influenza. 
Ekici, Keskinocak and Swann [36] classify disease spread modeling into four groups based on their 
solution methodology. This study focuses on the use of discrete event and agent based simulations 
because both of them allow for the optimization of complex models and stochastic modeling. The other 
two methods, differential equations and random graphs, present significant drawbacks for the purpose of 
this study, such as the use of continuous modeling of time or the creation of a detailed network that have 
nevertheless proven useful for localized, small scale simulation [13, 37]. 
Revenue Management theory is briefly described in the following section. 
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1.2 Revenue Management 
 
Revenue Management is loosely defined as a set of tools that companies use to optimize revenue by 
adjusting their supply given the demand of differentiated sets of customers [38]. The term is also used 
interchangeably with yield management [39] and can be summarized as “selling the right product to the 
right customer at the right time” [40]. 
The airline industry was first to implement Revenue Management to have more control over its 
reservation systems. The initial use of revenue management occurred in the 70s when some airlines began 
to offer different prices for passengers traveling in the same aircraft, based on early purchase decision. 
For the airlines, the problem was how to determine the number of seats to make available to different 
customer segments. In 1972, Littlewood [41] provided the solution to the problem. He stated that for a 
two class system, given that their demand distributions are known, no more products should be sold at a 
low price when selling them at a higher price yields higher expected revenue. 
The main barrier to implement revenue management came down in 1978 when the airline industry 
was deregulated, allowing airlines to freely  set their own seat prices [42]. American Airlines was the first 
to successfully implement Littlewood’s rule in 1985 [43]. Later, in 1987, Belobaba developed the theory 
behind Expected Marginal Seat Revenue, which is frequently cited as one of the triggers for the 
popularity of revenue management [40, 44]. It is used to determine the optimal number of items that 
should be reserved for a particular cohort, so that revenue is maximized by applying concepts from 
Littlewood’s rule [45].  
The influenza vaccine market exhibits characteristics that favor the implementation of Revenue 
Management theory. First, vaccine supply is limited and expanding production capacity is expensive and 
physically constrained by the current availability of eggs used for vaccine development. Second, vaccine 
doses are perishable and cannot be stored over multiple seasons, because flu strain viruses vary from year 
to year. Third, the vaccine market is segmented having population cohorts with difference Willingness To 
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Pay (WTP). Such WTP can result from different likelihoods of infection and complications particular to 
each cohort, as defined by the ACIP [38-40, 46]. 
 
1.3 Price Discrimination 
 
Price discrimination is commonly practiced by multiple industries, such as the airline or hotel industry, 
and even universities [47]. The main objective of price discrimination is to increase revenue by charging 
some consumers more than others [47]. Steinberg and Weisbrod [48] claim that in the case of nonprofit 
institutions, price discrimination arises out of the need to cover their costs and reach distribution and 
service levels goals, which is commonly observed when the price must be set below marginal cost, even 
zero. 
According to Norman [49] there are three degrees of price discrimination. The first one, referred as 
“perfect” price discrimination, maximizes the firm’s profit by charging the highest price the customer is 
willing to pay for every unit sold.  It is almost exclusively applied through bargaining due to the difficulty 
of determining the WTP for each customer. The second degree price discrimination allows the customer 
to select among a set of choices that best fit the customers’ preference. The last degree, also called market 
segmentation is the most common in the field of revenue management. Here, the seller divides the market 
into identifiable consumer groups who are charged a different price per unit [45, 49, 50]. 
Talluri and Van Ryzin [45] describe the essential features for any degree of price discrimination to be 
applicable. First, there has to be heterogeneity in customer preferences, as reflected by their willingness to 
pay. In the case of vaccines, the ACIP determines appropriate segmentation by risk group. The second 
condition is the inability of customers to purchase a product and then to resell it to other customers with 
higher willingness to pay for the item. In the case of vaccines, it is not feasible that a final user will resale 
the vaccines he/she has purchased, since vaccines are injected at the time of purchase. Finally, the last 
condition is the presence of market power which requires the companies to be able to dictate the market 
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price. In economic theory, market power takes place when the product is sufficiently different from others 
in the market and the price can be determined by the seller due to the lack of competition in the market. 
Therefore, a market governed by a monopoly or oligopoly is a clear example where the seller has market 
power [45]. The vaccine market has few manufacturers that satisfy all the market’s needs, thus resulting 
into an oligopolistic market [51].  Additionally, almost 50% of the vaccine supply in the United States is 
purchased by the government, which allows for high price control. 
Revenue Management theory presents two main methods to manipulate the demand of a single 
resource: price-based and quantity-based discrimination.  
Price-based discrimination requires the identification of demand curves for each of the distinctly 
identified groups. In Economics, an indifference curve models an individual’s tradeoff between two 
products [52]. A correlation between health and price of vaccines can be easily justified. For example, 
Maciosek et al. [53] estimated the savings due to vaccination based on the gains of QALYs measured by 
interpreting a gain in revenue as a reduction in the probability of infection among the population thus 
establishing a link between vaccine prices and the health of the population. When setting a price for any 
product, optimal pricing strategies recommend price changes at every time period if there are no pricing 
constraints in place [54]. While the rise of e-commerce has enabled firms to dynamically change prices 
[38], Gallego and van Ryzin [55] demonstrated that when limiting the number of price changes, namely to 
one, the solution to revenue management pricing problems is asymptotically optimal as long as the 
number of items is large and there is enough time to sell them. Similarly, Feng and Gallego [56] find the 
optimal time span for promotions to last and thus corroborate the previously stated finding. 
Alternatively, quantity-based discrimination uses the concept of allotment to reserve a certain amount 
of product for a particular group of customers. The use of allotment merely sets supply for each market 
segment to a fixed value. One of the drawbacks of allotment is that if there is an opportunity to sell an 
item to a segment that is willing to pay a higher price when that particular segment has reached the 
allotted quantity, it will be rejected because there is only space available in the lower class.  
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The origins of revenue management are usually attributed to Kenneth Littlewood who introduced the 
probability-based two-class decision rule, nowadays known as Littlewood’s Rule [38]. However, this 
formulation carries some important assumptions which are explained in depth by Talluri and van Ryzin 
[45]. 
In the case of influenza, the ACIP divides the US population into two distinct groups, based on their 
risk of becoming infected and their likelihood of complications [20]. Therefore, we propose a two-class 
problem as the best applicable approach to model the current seasonal influenza vaccination process.  
In this study, the two-class problem considers that one class pays a discounted price  and that the 
other one pays full price . The main question that needs to be answered is what these prices 
are. If the prices are too high then not all vaccines may be sold. If the prices are set too low, then it is not 
guaranteed that the vaccines will be distributed to the intended population cohort. Thus, setting adequate 







This study extends the disease spread model proposed by Larson [18] to allow for a wider array of cohorts 
and more opportunities for interaction among members of such cohorts. Furthermore, this thesis studies 
the effect of preferential vaccination for more risky population cohorts in order to effectively allocate 
vaccines to different cohorts when needed, by changing vaccine prices through an optimization 
mechanism. This mechanism maximizes vaccine availability for the high-risk cohorts. 
Two approaches are proposed to model the progression of influenza among the population. The first 
one tracks the spread of the disease over the different cohorts by capturing the effect that vaccine pricing 
has on the number of susceptible individuals in a population, and hence, its effect on the disease’s 
transmission rates.  The model includes an optimization method that determines the fractions of each 
population cohort that are willing to receive vaccination at every time period, given a particular vaccine 
price. The proposed optimization method aims to minimize the overall number of infections and deaths 
occurred during an influenza season, in order to achieve a condition where R0 ≤ 1 is induced at the earliest 
possible time by dynamically adjusting the vaccine price per dose for each risk group.  
The second approach uses a Monte Carlo agent-based simulation approach, which simulates the 
behavior of each individual in the population by introducing stochastic parameters. The pricing strategy 
can be guided towards optimality by adjusting the prices at every time period, however, the simulation of 
each time period has to be re-ran after every adjustment. Therefore, this approach is reduced to trial-and-
error, which becomes very resource intensive. It is important to note that both approaches are modeled 
based on the same structure.  
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Section 2.1describes the different stages of seasonal influenza. The parameters, nomenclature and the 
formulas that govern the transition between stages are described in Section 2.2. Sections 2.3 and 2.4, 
describe each of the discrete event simulation and agent-based simulation, respectively. Finally, the 
models’ assumptions are presented in section 2.5. 
 
2.1 Disease Transmission Model 
 
The disease transmission model used in this study is as an expansion of the Larson’s model, which is, in 
turn, and expansion of the traditional SIR model with seven possible states: Susceptible (S), Exposed (E), 
Infectious Asymptomatic (A), Infectious Symptomatic (I), Deceased (D), Vaccinated (V) and Recovered 
(R). Figure 1 illustrates the transition between these states. 
At the beginning of an influenza cycle, the entire population is susceptible to the seasonal influenza 
virus. It is only then, that a small group of people starts the infection spread. Once the infected population 
becomes contagious, commonly referred to as shedding, they mix with the susceptible population and 
infect them. Thus, a recently infected individual will go from susceptible one day to exposed the 
following day, during which the individual is carrying the virus but is neither aware of it nor shedding. 
Normally, this period is followed by either an infectious asymptomatic state or an infectious symptomatic 
one. During the asymptomatic state, the individual may infect others but present no symptoms, while the 




Figure 1: State Transition Diagram 
 
The number of people who become infected by each new infected individual is a function of the 
number of contacts the person has during states (A) and (I), and the probability of infection. It is 
commonly assumed that an infectious symptomatic person undergoes a voluntary isolation [19, 57] until 
he or she recovers, which results in a reduction of the contact rate with susceptible individuals in the 
population. While isolation is not a state in the progression of the disease, it is modeled as part of the 
symptomatic state by reducing the number of contacts by a constant factor. 
The transition into recovery from the infectious symptomatic state depends on the probability of 
recovery and the development of natural immunity against the virus. Additionally, to capture the effect of 
immunization, the proposed disease transmission model considers that immunity is also developed 
through vaccination. This study considers that the number of people who get vaccinated at a given point 
in time depends on the number of vaccines available and on the number of people willing and able to 
purchase a vaccine dose at the current given price. Finally, if an infected patient does not recover, his or 
her symptoms may worsen, which can lead to death. 
The following section describes the parameters used for the experimental case being modeled. 
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2.2 Disease Spread Model 
 
Models discussed in sections 2.3 and 2.4 use the following nomenclature to describe the behavior of the 




The following parameters are used to define the spread of the disease for the models presented in Sections 
2.3 and 2.4. 
Ni,k (t) = population from cohort i in state k  during time period t. 
λi,j,r = rate of contact of a person in cohort i with a person in cohort j, in r different settings where 
individuals i and j can meet. 
pi,j,r = probability that a susceptible person from cohort i, given contact with an infected, contagious 
person from cohort j, becomes infected in setting r. 
p
D
i = probability that an infected person from cohort i dies due to influenza. 
 
Therefore, the probability that in period t a person in cohort i is in contact with an infectious 
individual is given by the fraction of contacts from the entire population that are infectious, and it is given 
by 
 













The probability of infection of a susceptible individual of cohort i in period t depends on the daily 
behavior of the individual and his or her susceptibility to the virus. Assuming Poisson-distributed 
interactions with means λi,j,r and a probability of contact βi,j,r(t), the probability of infection of an 
individual from cohort i in period t is given by 
 
                                          P
I





          
(2) 
 
VS(t) = number of available vaccines during time period t 
P
S
 = probability of any individual to develop symptoms after the incubation period. 
P
Q
 = probability that any individual, given the development of symptoms, will enter into a voluntary 
quarantine. 
The detailed model is shown on Figure 2 and includes all expressions used to describe state 
transitions. In particular, the population parameters include a time shift, which is related to the duration of 
the state for a disease. The parameters used in Figure 2 correspond to the seasonal flu and will be 
described in more detail in Chapter III. 





Figure 2: State transition diagram with duration of states for seasonal influenz
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2.2.2 Decision Variable 
 
The probability of an individual purchasing a vaccine is proportional to the number of people in 
the population that are willing and able to get vaccinated. Since this pricing model does not strictly 
exclude anybody from getting a vaccine –it only discourages people from early purchase—, all 
susceptible individuals and those unaware of having contracted the disease would be eligible for 
vaccination. It is assumed that anyone who has contracted the disease would develop natural 
immunity and, thus, not need the vaccine anymore. 
In economic theory, it is commonly assumed that the willingness to pay (WTP) of each 
individual is known and that it can be used to price discriminate [48]. The addition of the WTP of 
each individual derives the market demand curve  or the demand curve for any group i of 
individuals , where  [49], p represents a price set on the market and q the 
corresponding units of the product sold at that price. The demand function can also be represented 
by a cumulative distribution where Q(p) indicates the percentile of the market population that is 
willing to pay price p for an item. Thus , where N represents the total initial 
population [45]. 
Therefore, the term described below is used as a decision variable for the optimization model 
and as a parameter for the agent-based simulation, which is changed for every setting simulated. 
 
Qi(pi(t)) = percentile of the population in cohort i that can get vaccinated during time t when 
faced with price pi. 
 
For ease of notation Qi(t) = Qi(pi(t)), which is used indirectly for the optimization model in the 




















i (t) = probability of vaccination of a person from cohort i during time period t. 
 
In general, given that only high-risk (H) and low-risk (L) groups of cohorts are distinguished, 
only one variable per risk group is defined, even if multiple cohorts belong to such group.  
 
                                                           (4) 
 
Equation (4) indicates the range of values that the variables may take. Since they represent 
percentiles, they have to be between zero and one, where a percentile of 0 results from prices 
sufficiently high that nobody in the cohort is willing to purchase the vaccine at that time period. 
Conversely, a value of one represents a low enough price that everybody is willing to purchase the 
vaccine at time t. 
 





              
(5) 













(t) represents the number of individuals willing and able to get a vaccine dur ing time t. 
Since only two risk groups are defined, it is assumed that the percentiles for all cohorts belonging 





that will receive vaccination. Thus, the probability of vaccination for an individual in cohort i may 
be rewritten as depicted on Equation (7). 
 
                                                            P
V
i(t) = )(*)( tftQ
V
i
        
(7) 
 
2.3 Optimization Model  
 
The goal of introducing vaccination and other control strategies is to mitigate the spread of 
seasonal influenza among the population. R0 measure models the number of secondary infections 
on a daily basis. Thus, by minimizing the value of R0 over time, the influenza will have the least 
impact on the population. A similar approach has been previously studied by Tennenbaum [58], 
where he considers four cohorts defined by their risk and activity level and solves the formulation 
by using differential equations to minimize the value of R0. 
 












      
(8) 
 
Equation (8) provides an expression for R0 at each period t that is minimized at every time-
period during the duration of the influenza season. Figure 2 shows that the exposed state is related 
to the decision variable by Equation (9), where P
V
i(t) is a function of the decision variable as 
described by Equation (7). 








This approach will promise more accessible vaccines to individuals in high-risk cohorts as 
defined by the ACIP, i.e. high-risk individuals have a higher probability of becoming infected, 
infecting others, and experiencing complications. Meltzer [21] calculates that fifteen percent of the 
population included in the highest risk cohort for influenza infection are children, who account for 
4/5 of the total number of infections.  
For every time period, the formulas are defined recursively with respect to the percentile 
variable for the current time period. Then, the minimum for the objective function is found using 
the NMinimize function from Mathematica, which determines the best approach to solve the 
proposed problem based on its structure. The solution to the resulting problem is used as input for 
the next period iteration. The process is repeated until the number of infected people or the number 
of susceptible people falls below one.  
The next section presents the agent-based simulation logic used to represent the stochastic 
version of the same problem. 
 
2.4  Agent-Based Simulation 
 
The models from Chapter II assume a completely random mixing between individuals , allowing a 
person to interact with any other person based on the probability of interaction. The infectious 
process focuses on determining the population proportions to determine the rate of infection. This 
characteristic gives this model the attribute of a ‘true’ mass-action system as defined by de Jong et 
al. [59], which indicates that “the contact rate increases linearly with population density, but is 
independent of the total physical area, hence, of the total population size”. The concept derived 
from the kinetics of chemical reaction holds true when the density of individuals in an area is not 
too high [60]. 
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The assumptions of true mass-action indicate that as long as population proportions remain the 
same, all other parameters do not need to be modified to accommodate a change in population size 
as long as the population density for the identified region does not vary much as long as the 
population density remains relatively the same, all other problem parameters do not need to be 
modified to accommodate a change in population size. Similarly, the seed population to initiate 
infection should be also adjusted to reflect the proportion. 
The Monte Carlo simulation experiment for modeling the spread of the disease under the 
effect of vaccination at different price levels uses discrete time and a reduced population size to 
ease the computation time. The steps involved in this experiment are described next. 
 The model tracks the behavior of each individual within the population, simulating their 
interaction. The number of contacts for each individual is generated from a random number. If the 
interaction is between a susceptible and a shedding individual, an infection may occur. The state of 
each individual is also monitored to determine the overall probability of infection and, if infected, 
the individual’s progression through the different stages of the disease. Similarly, randomly, it is 
determined whether the individual develops symptoms or if she recovers from the disease. 
The pseudocode for the simulation is as follows: 
1. Initialize data – generate each agent and enough seeds for vaccination to begin 
2. For every day t  
a. Randomly allocate vaccines to cohorts based on population proportions 
i. Randomly assign allocated vaccines to individuals within each cohort 
b. For every individual n 
i. Randomly generate –using a Poisson distribution— the number of 
contacts each individual will have with individuals of other cohorts 
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1. Update β based on the number of infectious and non-
infectious from the randomly generated numbers 
c. For every individual n 
i. If individual is susceptible 
1. For every contact c 
a. Randomly determine if the contact was with an 
infectious individual based on probability β  
b. If infectious contact 
i.  Randomly determine if the person got 
infected based on the probability of infection 
ii. Else if individual is in last day of incubation 
1. Randomly determine the next stage in the disease progression 
based on the probability of becoming symptomatic 
iii. Else if individual is in last day of symptomatic state 
1. Randomly determine if the individual recovers or dies 
iv. Else 
1. Determine the next state in the progression of the disease 
 
2.5 Models Assumptions and Limitations 
 
Given that influenza is modeled within a 180-day period [57], for the sake of simplicity, the model 
assumes that no major changes in the population occur as a consequence of its relatively short 
duration. Thus, births and deaths are not considered in the models presented in Sections 2.3 and 
2.4. However, if needed, births could be added as a periodic increase in the susceptible population 
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of the youngest cohort. Likewise, since the effect of deaths due to other diseases is not considered, 
it may be modeled as a similar decrease in the size of each of the cohorts. 
The models described in Sections 2.3 and 2.4 do not capture geographical distribution of the 
population and it does not account for traveling between locations. The models are not concerned 
with how the disease spreads between major population hubs and smaller cities, or across the 
country. 
Other mitigation strategies, such as school closures could be considered in the model. The 
results of this type of policy may be implemented by defining one of the settings in the average 
daily contacts matrix so that it corresponds to a school. 
Hospitalization can be modeled by adding an extra stage in the transmission model. Additional 
parameters are needed to describe the behavior of the individuals within the hospital, the 
probability of getting better or worsening, as well as the likelihood of transmission. 
It is also assumed that one single vaccine provides perfect protection to an individual [58]. 
Modeling the need for a second vaccine can be accomplished by introducing a state for those 
individuals that have received one vaccine but not the second. Reducing the effect of the vaccine 
can be done by reducing the probability of infection for the people that have been vaccinated, 
which allows them to still become infected but at a reduced rate. Other methods of prevention such 
as Targeted Antiviral Prophylaxis (TAP) are deemed inaccurate, labor-intensive, and possibly only 









The purpose of this chapter is to describe an instance of parameters [19, 57, 61-63] that will be 
applied to model 2.3. The results will be tested against existing literature that uses similar 
modeling parameters. Section 3.1 describes features of the influenza and the population. Section 
3.2 describes the experiments, followed by the results on Section 3.3. 
 
3.1 Model Parameters 
 
Clinical trials have been used to study the behavior of the influenza virus in humans and tried to 
determine its effect among different groups, commonly aged 0-5 years, 5-9 years, 10-14 years, 15-
18 years, 19-64 years, and >65 years [64, 65]. Lee et al. [19] and Germann et al. [57] show that, 
once infected, the incubation period has an average length of two days. When the individual 
begins shedding, there is a 33% chance that he or she does not present symptoms. Therefore, this 
person is assumed to be half as likely to infect a susceptible individual than a symptomatic one 
[57]. Those that show symptoms are likely to enter voluntary isolation. A common assumption is 
that the population will be 50% compliant with such isolation [19, 57]. This means that half of the 
populations with symptoms will go to work or school while sick. Those that begin isolation are 
assumed to have no contact with people outside their household [66]. The average infection period 
has been found to be seven days, after which symptomatic individuals either recover or die [19, 




Population numbers from the U.S. Census Bureau [63] indicate that 6.8% of the population is 
<5 years of age, 7.3% is in the 5-9 age group, 7.3% is in the 10-14 age group, 7.2% are 15-18 
years old, 59% of the population are adults aged 19-64, and 12.4% are >65 years. These numbers 
closely follow the work from Longini et al. [61].  
This study assumes that the supply of seasonal vaccines is similar to that of the 2009 H1N1 
pandemic, where 91 million vaccines were available to the U.S. population. It is important to note 
that the current amount of seasonal flu vaccine can only cover up to 30% of the total population 
[4]. The stockpile of vaccines is commonly released in large quantities throughout the duration of 
the infection. The model presented in this section uses the probability for the next batch of 
vaccines to be released on any given day. 
 
 
Figure 3: Sample vaccine supply curve for 2005 [68] 
 
Based on previously CDC reported dates of distribution for influenza vaccines [68], this study 
suggests an equation that describes the monthly vaccine availability. This study fits a curve to the 
presented vaccine distribution from Figure 3 to describe a daily availability. The fitted curve keeps 
the number of monthly distributed vaccines equal to the data presented from previous years but 
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spread over all days of the month, while keeping the trend of vaccine arrival. Thus, following the 
data from Figure 3, 8% of the vaccines will have arrived by the end of the first month, 34% by the 
end of the second, and so on.  
The model developed to describe the spread of the disease is described in the next section. 
 
3.1.1 Population Interaction Parameters 
 
The input required by both models is similar to that presented by Lee et al. [19], Germann et al.  
[57] and Longini et al. [61]. These authors, ran an agent-based simulation study on the proportion 
of the working population that need to be vaccinated to mitigate a pandemic, a simulation study 
based on community interactions to test the effect of combinations of intervention strategies, and 
an agent-based simulation study to determine the effect of targeted vaccination distribution 
techniques, respectively. We use population proportions for each cohort as given by the U.S. 










1 0-5 6.8 Pre-school 
2 5-9 7.3 Elementary School 
3 10-14 7.3 Middle School 
4 14-18 7.2 High School 
5 19-64 59.0 Adult 
 19-24 6.8 Adult 
 25-44 30.2 Adult 
 45-64 22.0 Adult 
6 >65 12.4 Adult 
Table 1: Population proportion by cohorts 
 
We model the behavior of the population based on the average number of contacts they have 
with individuals from different cohorts, as seen on Table 2. The agent-based simulation generates 
a random number from a Poisson distribution using the mean daily contacts to generate the 
number of contacts each individual will have with every cohort. The optimization model feeds the 
average number of contacts into an equation to calculate the expected number of contacts with 
each cohort and estimate the likelihood that an infected individual will meet a susceptible one.  In 
Table 1, cohorts 1-4 are represented by the ‘Student’ label; cohorts 5 and 6 are represented by the 
‘Adult’ label on Table 2. The models do not differentiate between days of the week. Therefore, all 
weekly activities, such as Classroom, School (not classroom), and Workplace are multiplied by the 
number weekdays in a week (0.71). Conversely, the Weekend setting is reduced by the ratio of 
weekend days in a week, namely 0.29. All other setting values are described below. 
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Setting Participant 1 Participant 2 
Mean Daily 
Contacts 
Classroom Student Student 13.5 
School (not classroom) Student Student 15 
Community Student Student 16.2 
Weekend Student Student 24.3 
Workplace Adult Adult 10 
Community All All 32.4 
Household Student Adult 2 
Household Student Student 1 
Household Adult Adult 1 
Table 2: Population Mixing Parameter 
 
A corresponding metric is based on the probability of infection given the contact between an 
individual that is shedding and a susceptible one. This parameter depends on who the infected 
individual is and his or her relation with the susceptible person. Table 3 shows the values used for 
the parameter in which the row label indicates the location where the infected individual from the 
indicated cohort becomes in contact with a susceptible one. The same labeling as Table 2 holds 





















Large day-care centers 1 0.04         
Elementary School 2   0.0435       
Middle School 3     0.0375     
High School 4       0.0315   
Family            
Student 1-4 0.6 0.6 0.6 0.6 0.3 
Adult 5-6 0.3 0.3 0.3 0.3 0.4 
Workplace 5         0.0575 
Community 1-6 0.00255 0.00255 0.00255 0.00255 0.0048 
Table 3: Probability of transmission given an infectious contact 
 
Figure 4 displays the smoothed curve representing a daily distribution and availability of 
vaccines. Both models are assumed to start with enough initial infected individuals among the 
population so that during the first day of the simulation, the population may be vaccinated. This 
model assumes that an individual from a particular cohort will purchase a vaccine with a 









The models were implemented in Mathematica 7.0 at The RIT’s Research Computing center. The 
purpose of the experiment is to determine if there are any additional gains that may be obtained by 
imposing a price discrimination scheme, when compared to a scenario where, depending on 
vaccine availability, all individuals are equally likely to get vaccinated. 
Three particular models are used for experimentation. The first one, baseline experiment, 
assumes that no vaccines are available for the population. Therefore, the only way to get immunity 
to the virus is through recovery from the disease. This model is used to determine the actual effect 
of the disease on the population. 
The second experiment assumes that vaccines are available, in accordance with Figure 4. 
However, this experiment assumes that vaccines are distributed throughout the population at no 
cost to the individual, i.e. without consideration for priority. This model allows calculating the 



























behavior of the population in the United States during the influenza season, where there are no 
price differences for cohorts. For validation, this experiment assumes that the ACIP priority, to 
first vaccinate individuals in high-risk cohorts, is not followed. This experiment’s results are then 
compared against Lee’s base model for validation. 
In the third experiment a percentile is calculated to offset the demand of vaccines from low-
risk cohorts, as described in Section 2.3. This model, when compared with the second one, allows 
estimating the gains from the introduction of price discrimination, thus enforcing the ACIP 
prioritization. 




The effectiveness of the model can be shown by the decrease in the total number of infections and 










Model 1: No Vaccination 96 34.9% 144,582 
Model 2: Free Vaccination 124 31.1% 128,499 
Model 3: Priced Vaccination 123 27.4% 113,472 




The scenario with no vaccination shows the highest spread of the disease within the population 
but, in this case, the disease got under control the fastest. The majority of the population got 
infected and, thus, the control comes from natural immunity. The model where there is no 
preference in vaccination and the one we proposed in this thesis were contained in the same time. 
The percentage of infections and deaths under no price discrimination closely follows Lee’s 
results. However, by better allocating the vaccines through price discrimination, the number of 
infections and deaths was reduced by 12%. 
 
 
Figure 5: Spread of the disease over time 
 
It can be noted, from Figure 5, that the infection spreads through the population at a faster rate 
when no vaccination is used. The peak of the disease also happens earlier than when 
countermeasures are presented. 
On Figure 6 some interesting points can be observed. At Point A, the tradeoff for vaccination 
is noticed, when the value of R0 starts rising. Here, the percentile of the high-risk population starts 










































reproduction number goes below one, at Point B, it is assumed that herd immunity is achieved 
[69]. This happens because most of the infections are caused by the high-risk group. At this 
moment, vaccines become available to the low risk population, at Point C, which still has some 
risk of infection. When the R0 value tapers off, the model finds that there is no difference to 
allocate vaccines to any one particular group as seen at the end of the graph, at Point D. 
 
 
































Policy makers are constantly looking for strong evidence of effectively mitigating the spread of 
infectious disease. The 2009 influenza season revealed discrepancies regarding the distribution of 
the vaccines to people of different risk groups. Some vaccination clinics strictly enforced the 
recommendations from the ACIP, while others administered the vaccine at normal cost to the 
entire population. 
This study presented two models that allow simulating the spread of a disease in a 
heterogeneous population setting. The model has been validated against another study and an 
appropriate vaccination process was introduced to the model. 
 An innovative approach for optimal allocation of vaccines was developed to determine 
appropriate vaccine distribution among different cohorts. With the given set of experimental 
conditions, the results clearly demonstrate a significant potential for the prevention of infections 
and deaths by temporarily enforcing the vaccination of high-risk individuals by postponing 
vaccination of those with lower risks. However, further research modeling various conditions is 
needed to generalize the results. Through pricing control the option of vaccination is not stripped 
away from the population but rather discouraged through price discrimination.  
A price-discrimination policy can be enforced through cooperation with insurance companies 
or as a discount in pricing at the vaccination clinics. Either way, government subsidy is still 
heavily required to control the oligopoly of vaccines, which is also a requirement for 
implementing Revenue Management. 
Pricing strategies particular to Revenue Management give the option of either establishing an 
optimal price to defer vaccination in low-risk cohorts or setting a quantity limit for each risk 
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group. The optimal value of either approach can be easily derived from a cumulative demand 
curve through the percentile approach presented. 
A possible estimation for determining a demand curve is presented in the appendix section. 
Demand for vaccines is also estimated yearly by the CDC, which can be used to better 
approximate the demand curve. Further, studies should be run to better understand the effect of 






The expansion of this model makes it possible to use with other diseases since its structure is very 
flexible and it allows for ease of implementation with other types of pandemics. A model where 
the parameters and constraints can be adjusted to simulate the effects of a different disease may 
also be developed as it has been shown that population size minimally affects its design. 
A more user-friendly environment can be helpful to promote its use and study. Through a 
well-designed user interface, other policies could be implemented and tested. As it was shown, the 
current model can accommodate other mitigation strategies such as school closures. 
Mathematica allows for the development of dynamic models that can be used to test single-
price models, for example. The author of this thesis has developed a small model, but the 
computing intensity makes its use cumbersome. In this sense, some time can be spent improving 
the efficiency of the code to allow for an interactive model. 
Further studies can be run to more accurately depict the consumer behavior in the case of a 
pandemic. The Lorenz Curve approximation may serve as an initial approach to develop demand 
curves for each risk group or cohort. As well, a survey can be conducted to study the reaction of 
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A. An Idea on Demand Curve Estimation 
 
In economic theory it is common to assume the WTP from each individual to be known and can be 
used to price discriminate [48]. In this study a possibility for modeling the cumulative demand 
curve is presented. Hansen, Formby and Smith [70] has previously demonstrated the use of the 
Lorenz Curve (LC) to determine the elasticity of the housing market. Similarly, it may be feasible 
to estimate the optimal reservation prices for the vaccine market.  
Moothathu [71] suggests the use of a Pareto distribution to generate data and plot a Lorenz 
curve, which describes the distribution of wealth among a particular population. The US Census 
Bureau has published the Gini coefficient [72], which measures the inequality of wealth 
distribution and placed it around 0.42. 
 
Figure 7: Wealth distribution in the United States  
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Figure 7 was derived with a Pareto distribution with parameters k = 1.4 and α = 1.23. The 
graph presented on the top-left corner represents the assumed demand curve for the population. To 
simplify the example, we assume that all cohorts have the same cumulative probability 
distribution. The graph refers to the percent of the population (y-axis) that would be willing and 
able to purchase a vaccine dose at the set corresponding price (x-axis). 
 
